XGXia Gu

Xia Gu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xia Gu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Bo Yu

    Department of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China

    1 shared publication
  • Jinwei Tian

    Department Of Cardiology, The Second Affiliated Hospital Of Harbin Medical University, Harbin, China

    1 shared publication
  • Sining Hu

    Key Laboratories of Education Ministry for Myocardial Ischemia; Department of Cardiology, Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, P.R. China

    1 shared publication
  • Xiang Ban

    Department of Pathology, Harbin Medical University, Harbin, China

    1 shared publication
  • Yanli Sun

    Key Laboratories of Education Ministry for Myocardial Ischemia; Department of Cardiology, Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, P.R. China

    1 shared publication
  • Yun Xiao

    College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China

    1 shared publication

Latest Publications

  • Open Access

    Effect of statin therapy on the progression of coronary atherosclerosis

    by Jinwei Tian, Xia Gu, Yanli Sun, Xiang Ban, Yun Xiao, Sining Hu, Bo Yu

    Background: An increasing number of authors employing intravascular ultrasound (IVUS) and virtual histology (VH-IVUS) have investigated the effect of statin use on plaque volume (PV) and plaque composition. However, inconsistent results have been reported. Therefore, we conducted a meta-analysis to determine the appropriate regimen of statins to effectively stabilize vulnerable coronary plaques. Methods: Online electronic databases were carefully searched for all relevant studies. We compared mean values of PV and plaque composition between baseline and follow-up in patients receiving statin therapy. We pooled treatment effects and calculated mean differences (MD) with the 95% confidence interval (CI) using a random-effects model. By stratified analyses, we explored the influence of clinical presentation, dose and duration of statin treatment, and low-density lipoprotein-cholesterol (LDL-C) levels on the effects of statins. Results: Seventeen studies involving 2,171 patients were analyzed. Statin therapy significantly decreased PV (−5.3 mm3; 95% CI: –3.3 mm3 to −7.2 mm3; P < 0.001), without heterogeneity. When considering the dose and duration of statins used, only subgroups employing a high dose and long duration demonstrated a significant reduction in PV (p < 0.001). A significant decrease in PV was noted if achieved LDL-C levels were p < 0.001). Statin treatment could induce a twofold decrease in PV in patients with acute coronary syndrome (ACS) compared with that observed in patients with stable angina pectoris (SAP). A regressive trend was seen for necrotic core volume (MD: –2.1 mm3; 95% CI: –4.7 mm3 to 0.5 mm3, P = 0.11). However, statin use did not induce a significant change for fibrotic, fibro-fatty, or dense calcium compositions. Conclusions: Our meta-analysis demonstrated that statin therapy (especially that involving a high dose and long duration and achieving <100 mg/dL LDL-C levels) can significantly decrease PV in patients with SAP or ACS. These data suggested that statins can be used to reduce the atheroma burden for secondary prevention by appropriately selecting the statin regimen. No significant change in plaque composition was seen after statin therapy.